Explore the groundbreaking strides in pediatric neurosurgery with our deep dive into the development of a 23-gene expression signature that revolutionizes the molecular subtyping of medulloblastoma, offering new hope for targeted therapies in a long-term Chinese cohort.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort.
Wang et al., Acta Neurochir (Wien) 2024
<!– DOI: 10.1007/s00701-024-05922-5 //–>
https://doi.org/10.1007/s00701-024-05922-5
Summary of New Findings:
A novel 23-gene signature has been identified that can accurately classify medulloblastoma, the most common childhood malignant brain tumor, into its molecular subgroups with a high classification accuracy of 95.2%. This gene signature was validated in a cohort of 142 Chinese patients, showing distinct survival rates across the subgroups. The signature’s subgroup assignments were highly comparable to Northcott’s NanoString assay with a concordance rate of 96.4%.
Importance:
The ability to classify medulloblastoma into molecular subgroups is crucial for personalized treatment strategies. This gene signature provides a reliable tool for clinical subtyping, which can potentially improve patient management and outcomes.
Contribution to Literature:
The study contributes to the literature by establishing a gene expression-based method for the subtyping of medulloblastoma, which is critical for the development of subgroup-specific therapies. It also provides survival statistics for the subgroups, which could be valuable for prognostic assessments.
Results in Detail:
- The 23-gene signature classified medulloblastoma patients into WNT (15%), SHH (29%), Group 3 (11%), and Group 4 (45%) subgroups.
- 5-year overall survival rates were 80% for WNT, 62% for SHH, 27% for Group 3, and 47% for Group 4 (p < 0.0001).
- 5-year progression-free survival rates were 80% for WNT, 52% for SHH, 27% for Group 3, and 45% for Group 4 (p < 0.0001).
- SHH/TP53-mutant tumors had a worse prognosis compared to SHH/TP53 wild-type tumors and other subgroups.